Alto Ingredients (ALTO) Panoramica del titolo
Alto Ingredients, Inc. produce, distribuisce e commercializza alcoli speciali, carburanti rinnovabili e ingredienti essenziali negli Stati Uniti. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 0/6 |
| Crescita futura | 3/6 |
| Prestazioni passate | 3/6 |
| Salute finanziaria | 4/6 |
| Dividendi | 0/6 |
ALTO Community Fair Values
Create NarrativeSee what 19 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
An Undervalued 3.3Moz Gold Project in Canada
Key takeaways Upside Gold is developing the Kena Gold Project, near the town of Nelson in the Kootenays region of southern British Columbia. Kena hosts a historical gold resource of 3.33 million ounces (561,000 ounces Indicated and 2.77 million ounces Inferred) across a 10,200-hectare land package.
Read full narrativeConcorrenti di Alto Ingredients, Inc.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$5.99 |
| Massimo di 52 settimane | US$6.00 |
| Minimo di 52 settimane | US$0.80 |
| Beta | 0.14 |
| Variazione di 1 mese | 28.27% |
| Variazione a 3 mesi | 126.89% |
| Variazione di 1 anno | 606.28% |
| Variazione a 3 anni | 281.53% |
| Variazione a 5 anni | 6.11% |
| Variazione dall'IPO | -99.41% |
Notizie e aggiornamenti recenti
ALTO: MASH And Alcohol-Related Liver Programs Will Drive Future Upside Potential
Alto Ingredients' analyst fair value estimate has shifted from $4.00 to $6.75 as analysts factor in updated assumptions on discount rate, revenue growth, margins, and a higher future P/E in light of recent bullish coverage and revised price targets tied to pemvidutide's MASH and alcohol-related disease programs. Analyst Commentary Bullish Takeaways Bullish analysts are focused on pemvidutide as a differentiated asset for MASH and alcohol-related liver disease.
ALTO: Future Returns Will Depend On MASH Trials And Alcohol Liver Data
Analysts have raised Alto Ingredients' price target to $25 from $12, citing pemvidutide's potential in MASH and alcohol-related liver and use disorders as key factors behind the revision. Analyst Commentary Recent Street research on Alto Ingredients highlights a mixed backdrop, with optimistic views on pemvidutide and the MASH program set against more cautious assessments of risk and valuation.ALTO: Future Returns Will Hinge On MASH Trials And Funding Discipline
Analysts have raised their average price target for Alto Ingredients to $25 from $12, citing a sharpened focus on the planned MASH pivotal program and added potential value from pemvidutide in alcohol use disorder and alcohol liver disease, along with a solid cash runway and upcoming clinical catalysts. Analyst Commentary Recent Street research on Altimmune reflects a mix of optimism around the clinical pipeline and caution around execution risks and valuation.Recent updates
ALTO: MASH And Alcohol-Related Liver Programs Will Drive Future Upside Potential
Alto Ingredients' analyst fair value estimate has shifted from $4.00 to $6.75 as analysts factor in updated assumptions on discount rate, revenue growth, margins, and a higher future P/E in light of recent bullish coverage and revised price targets tied to pemvidutide's MASH and alcohol-related disease programs. Analyst Commentary Bullish Takeaways Bullish analysts are focused on pemvidutide as a differentiated asset for MASH and alcohol-related liver disease.ALTO: Future Returns Will Depend On MASH Trials And Alcohol Liver Data
Analysts have raised Alto Ingredients' price target to $25 from $12, citing pemvidutide's potential in MASH and alcohol-related liver and use disorders as key factors behind the revision. Analyst Commentary Recent Street research on Alto Ingredients highlights a mixed backdrop, with optimistic views on pemvidutide and the MASH program set against more cautious assessments of risk and valuation.ALTO: Future Returns Will Hinge On MASH Trials And Funding Discipline
Analysts have raised their average price target for Alto Ingredients to $25 from $12, citing a sharpened focus on the planned MASH pivotal program and added potential value from pemvidutide in alcohol use disorder and alcohol liver disease, along with a solid cash runway and upcoming clinical catalysts. Analyst Commentary Recent Street research on Altimmune reflects a mix of optimism around the clinical pipeline and caution around execution risks and valuation.ALTO: Future Returns Will Depend On Execution And Funding Discipline
Analysts have raised their price target on Alto Ingredients to $4.50 from $3.00, citing updated assumptions around fair value, discount rate, expected revenue growth, profit margins, and future P/E that they say are more in line with recent Street research on comparable companies. Analyst Commentary While the higher price target reflects updated valuation work, some bearish analysts in the broader small cap space are still emphasizing execution and funding risks that can weigh on sentiment for companies like Alto Ingredients.ALTO: Future Upside Will Depend On Delivering Consistent Margin Execution
Analysts have adjusted their price target on Alto Ingredients to $3.00, with the neutral fair value and updated assumptions on discount rate, revenue growth, profit margin, and future P/E reflecting a refined view of the company’s risk and earnings profile following recent supportive research coverage. Analyst Commentary Recent research on Alto Ingredients has focused on reassessing the balance between potential upside and the risks tied to execution, earnings quality, and market conditions.ALTO: Fair Outlook Will Rely On Sustaining Margins And Execution
Analysts have raised their price target for Alto Ingredients to US$3.00, reflecting updated views that include modestly higher revenue growth, slightly stronger profit margins, a lower discount rate, and a revised future P/E assumption, supported in part by recent bullish Street research. Analyst Commentary While the updated US$3.00 price target points to a more constructive stance overall, some bearish analysts remain cautious and continue to flag risk around how Alto Ingredients can justify this valuation through execution and earnings delivery.ALTO: Upcoming Liver Meeting Data Will Support Repriced Risk Reward Profile
Analysts recently trimmed their 12 month price target on Alto Ingredients by US$1 to US$14, citing refreshed assumptions around discount rates, revenue growth, profit margins, and future P/E multiples. Analyst Commentary Bearish analysts trimming price targets on comparable small cap names to around US$14, even when maintaining constructive ratings, suggest a tighter margin for error around assumptions such as discount rates, revenue growth, profit margins, and future P/E multiples.ALTO: Upcoming Late-Stage Liver Data Will Support Repriced Risk Reward Profile
Narrative Update: Alto Ingredients Analyst Price Target Shift Analysts have trimmed their price target on Alto Ingredients by $1 to $14, citing updated risk and growth assumptions after the timing and outlook of recent clinical data were refined. Analyst Commentary Recent Street research reflects a more cautious tone, with bearish analysts trimming price targets and rechecking their assumptions on risk and potential upside.ALTO: Upcoming Late-Stage Data Will Shape Risk Profile Amid Measured Outlook
Analysts have modestly lowered their price target on Alto Ingredients, trimming fair value by $1 to $14 as they factor in slightly softer long term assumptions, while remaining encouraged by upcoming late stage data presentations. Analyst Commentary Bearish analysts have pointed to the recent price target reduction to $14 as evidence that expectations for Alto Ingredients' long term growth and profitability are being tempered, even as upcoming late stage data remains a potential catalyst.Alto Ingredients, Inc.'s (NASDAQ:ALTO) Shares Leap 41% Yet They're Still Not Telling The Full Story
Dec 22
ALTO: Lower Discount Rate Will Support Improved Risk Profile Ahead
Analysts have raised their price target on Alto Ingredients by about $0.50, citing a lower perceived risk profile driven by a reduced discount rate, stronger expected revenue growth, and a modest improvement in projected profit margins and future valuation multiples. Analyst Commentary Bearish analysts remain cautious on Alto Ingredients despite the recent upward revision to the price target, emphasizing that the new target still embeds a meaningful discount to peers on key growth and profitability metrics.Alto Ingredients, Inc. (NASDAQ:ALTO) Shares Fly 28% But Investors Aren't Buying For Growth
Nov 07Alto Ingredients, Inc. (NASDAQ:ALTO) Held Back By Insufficient Growth Even After Shares Climb 31%
Jul 04
CO2 Plant Integration Will Boost Production And Exports
Acquisition and integration of the CO2 processing plant are expected to improve financials through cost synergies, increased capacity, and enhanced revenue streams.Health Check: How Prudently Does Alto Ingredients (NASDAQ:ALTO) Use Debt?
Apr 22Alto Ingredients (NASDAQ:ALTO) Is Making Moderate Use Of Debt
Nov 12Alto Ingredients, Inc.'s (NASDAQ:ALTO) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Jul 17Would Alto Ingredients (NASDAQ:ALTO) Be Better Off With Less Debt?
Jun 28Here's Why Alto Ingredients (NASDAQ:ALTO) Can Afford Some Debt
Jan 15Alto Ingredients, Inc. (NASDAQ:ALTO) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Dec 20Is Alto Ingredients (NASDAQ:ALTO) A Risky Investment?
Sep 15We Think Alto Ingredients (NASDAQ:ALTO) Has A Fair Chunk Of Debt
Apr 10Is Alto Ingredients (NASDAQ:ALTO) A Risky Investment?
Dec 16Alto Ingredients: The Decline Has Created A Buying Opportunity
Oct 19Alto Ingredients gains on announcing $50M share repurchase program
Sep 12Alto Ingredients (NASDAQ:ALTO) Seems To Use Debt Quite Sensibly
Aug 31Alto Ingredients: Cheap For A Reason
Jul 31With EPS Growth And More, Alto Ingredients (NASDAQ:ALTO) Makes An Interesting Case
Jun 18Rendimenti per gli azionisti
| ALTO | US Chemicals | US Mercato | |
|---|---|---|---|
| 7D | 13.4% | 0.6% | 1.8% |
| 1Y | 606.3% | 13.4% | 29.8% |
Ritorno vs Industria: ALTO ha superato il US Chemicals che ha restituito 13.4 % nell'ultimo anno.
Rendimento vs Mercato: ALTO ha superato il mercato US che ha restituito 29.8 % nell'ultimo anno.
Volatilità dei prezzi
| ALTO volatility | |
|---|---|
| ALTO Average Weekly Movement | 18.0% |
| Chemicals Industry Average Movement | 7.3% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di ALTO è stato volatile rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 18% ) di ALTO è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni US.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 2003 | 390 | Bryon McGregor | www.altoingredients.com |
Alto Ingredients, Inc. produce, distribuisce e commercializza alcoli speciali, carburanti rinnovabili e ingredienti essenziali negli Stati Uniti. L'azienda opera in tre segmenti: Marketing e distribuzione, Produzione del campus di Pekin e Produzione occidentale. L'azienda offre alcoli speciali utilizzati per collutori, cosmetici, prodotti farmaceutici, igienizzanti per le mani, disinfettanti e detergenti per i mercati della salute, della casa e della bellezza; spiriti neutri di cereali utilizzati per le bevande alcoliche e l'aceto, nonché germe di mais utilizzato per gli oli di mais nei mercati degli alimenti e delle bevande; alcoli e altri prodotti per applicazioni di verniciatura e fertilizzanti nei mercati dell'industria e dell'agricoltura; e ingredienti essenziali, tra cui lievito secco, farina proteica di mais, mangimi proteici di mais, germe di mais, grani di distillatori e mangimi liquidi per applicazioni di mangimi commerciali per animali e alimenti per animali domestici, nonché lievito e gas CO2 liquido per il consumo umano.
Alto Ingredients, Inc. Riepilogo dei fondamenti
| ALTO statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$422.80m |
| Utili (TTM) | US$12.07m |
| Ricavi(TTM) | US$917.93m |
ALTO è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| ALTO Conto economico (TTM) | |
|---|---|
| Ricavi | US$917.93m |
| Costo del fatturato | US$883.01m |
| Profitto lordo | US$34.91m |
| Altre spese | US$22.84m |
| Utili | US$12.07m |
Ultimi utili riportati
Dec 31, 2025
Prossima data di guadagno
May 06, 2026
| Utile per azione (EPS) | 0.16 |
| Margine lordo | 3.80% |
| Margine di profitto netto | 1.32% |
| Rapporto debito/patrimonio netto | 32.5% |
Come si è comportato ALTO nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/05 07:09 |
| Prezzo dell'azione a fine giornata | 2026/05/05 00:00 |
| Utili | 2025/12/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Alto Ingredients, Inc. è coperta da 9 analisti. 2 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Carter Driscoll | B. Riley Securities, Inc. |
| Hamed Khorsand | BWS Financial Inc. |
| Eric Stine | Craig-Hallum Capital Group LLC |